stockrow
Saturday 7 November 2026
Export BDTX’s income statement to Excel — free account
Black Diamond Therapeutics, Inc.
BDTX Healthcare Biotechnology
Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million.
- EPS
- +10.5%
- Free cash flow
- +12.9%
Quarter to June 2026, against a year earlier
1.73
0.07
+4.22%
Follow BDTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 70 | — | — | 6 | 6 | 6 | (55.3%) | |
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 100.00 | 0.00 | +100.0 pt | ||||||
| EBT | — | (5) | (9) | (35) | (67) | (126) | (89) | (82) | (70) | 22 | (43) | n/m | ||||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.95 | 0.00 | +32.0 pt | ||||||
| Net income | — | 0 | (9) | (35) | (67) | (126) | (91) | (82) | (70) | 22 | (43) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.23 | 0.00 | n/m | |||||
| Earnings | — | (0.13) | (4.42) | (16.99) | (2.05) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 | (0.75) | n/m | ||||||
| Cash flow | — | (0.07) | (4.19) | (11.89) | (1.58) | (2.77) | (2.34) | (1.52) | (1.13) | 0.52 | (0.57) | n/m | ||||||
| Capex | — | 0.00 | (0.04) | (0.01) | 0.00 | (0.07) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | (0.07) | (4.22) | (11.90) | (1.59) | (2.84) | (2.35) | (1.52) | (1.13) | 0.52 | (0.57) | n/m | ||||||
| Book value | — | (0.19) | (7.70) | (22.72) | 9.35 | 5.41 | 3.18 | 2.66 | 1.51 | 1.97 | 1.68 | n/m | ||||||
| Shares, m | — | 36 | 2 | 2 | 33 | 36 | 36 | 44 | 55 | 57 | 57 | +5.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 6.23 | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | 1.23 | 1.03 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | 0.32 | 0.34 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | (2) | (8) | (25) | (52) | (100) | (85) | (67) | (62) | 30 | (33) | n/m | |||||
| Capex | — | 0 | 0 | 0 | 0 | (3) | 0 | 0 | 0 | 0 | 0 | n/m | ||||||
| Free cash flow | — | (2) | (9) | (25) | (52) | (103) | (85) | (67) | (62) | 30 | (33) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 6 | 49 | 151 | 305 | 192 | 112 | 114 | 81 | 117 | 100 | +45.9% | |||||
| Net debt | — | 5 | (52) | (155) | (315) | (210) | (123) | (131) | (99) | (129) | (111) | n/m | ||||||
| Shareholders’ equity | — | (7) | (16) | (47) | 308 | 196 | 116 | 117 | 83 | 112 | 96 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (15.38) | (34.47) | (33.56) | (27.57) | (43.51) | (45.14) | (52.37) | (49.55) | 16.84 | (29.21) | +32.2 pt | |||||
| ROIC | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | 41.43 | 80.40 | 112.47 | (51.61) | (49.87) | (58.52) | (70.94) | (69.67) | 22.88 | (37.21) | (18.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 31 | 32 | 73 | 88 | 65 | 54 | 24 | 21 | — | (5.4%) | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.33 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2025 · fundamentals updated 26 Oct 2026
Black Diamond Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IMUX Immunic, Inc. | $99.9M | — (loss-making) | — | — | n/m | −26.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NRXP NRx Pharmaceuticals, Inc. | $98.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | Compare |
| UNCY Unicycive Therapeutics, Inc. | $96.9M | — (loss-making) | — (loss-making) | — | n/m | +9.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PMVP PMV Pharmaceuticals, Inc. | $96.3M | — (loss-making) | — | — | n/m | +20.27% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDTX Black Diamond Therapeutics, Inc. | $95.4M | — (loss-making) | — (loss-making) | — | n/m | +12.91% (above 0%: growing) | 100.00% | 0.00% | |
| LENZ LENZ Therapeutics, Inc. | $94.6M | — (loss-making) | — (loss-making) | −72.93% (below 0%: shrinking) | n/m | −147.16% (below 0%: shrinking) | 86.58% | (972.75%) | Compare |
| VANI Vivani Medical, Inc. | $93.8M | — (loss-making) | — (loss-making) | −71.87% (below 0%: shrinking) | n/m | +0.39% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VXRT VAXART, INC. | $92.4M | 2.8× | — (loss-making) | −85.33% (below 0%: shrinking) | n/m | −57.23% (below 0%: shrinking) | 100.00% | (162.74%) | Compare |
| NMRA Neumora Therapeutics, Inc. | $91.5M | — (loss-making) | — | — | n/m | +24.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $95.4M | — | — | −72.93% | — | −13.20% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 29 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 2.23m | 2.57m | 89.00 |
| 2024 | 2.86m | 1.95m | 76.00 |
Ownership
Directors and executive officers, together
9.29%
Entities affiliated with T. Rowe Price Investment Management
18.73%
Entities affiliated with Versant Venture Capital
10.83%
Entities affiliated with New Enterprise Associates
7.76%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement